**Supplementary Table 2: Treatment outcomes of 22 patients undergoing POEM-SSMD.**

|  |  |
| --- | --- |
| **Clinical efficacy of POEM-SSMD** | |
| Eckardt score, median (range) |  |
| Pre-treatment | 6.5 (4–11) |
| Post-treatment | 1 (0–6) |
| Treatment success rate (Eckardt score ≤3), *n* (%) | 15/18 (83.33) |
| LESP, mean (range) (mmHg) |  |
| Pre-treatment | 21.68 (16–32.9) |
| Post-treatment | 7.26 (0.7–11.5) |
| **Improvement in quality of life** | |
| AE-18 score, median (range) |  |
| Pre-treatment | 69 (54–79) |
| Post-treatment | 87 (67–89) |
| Improvement rate, *n* (%) | 16/18 (88.9) |
| **Clinical reflux adverse events, *n* (%)** | |
| Reflux esophagitis (Los Angeles classification B/C) | 2 (11.1) |
| Esophageal acid exposure | 1 (5.5) |
| Symptomatic reflux | 6 (33.3) |

LESP: Lower esophageal sphincter pressure; POEM-SSMD: Peroral endoscopic myotomy with simultaneous submucosal and muscle dissection.